Department of Pulmonary Medicine, C. S. M. Medical University UP, Lucknow, India.
Biosci Trends. 2010 Apr;4(2):48-55.
The occurrence of resistance to drugs used to treat tuberculosis (TB), and particularly multi-drug resistant TB (MDR-TB) defined as resistance to at least rifampicin and isoniazid, has become a significant public health dilemma in a number of countries and an obstacle to effective global TB control. HIV-associated MDR-TB understanding is vital in providing strategies for treatment of HIV and drug-resistant TB. Better understanding on the basis of drug action and resistance is a key to development of diagnostic strategies, novel drugs, and treatment programs, and to find an approach to study the pathogenicity of drug resistant strains. The effectiveness of strategies such as DOTS-Plus in the management of MDR-TB patients under program conditions should be tested in operational field clinical trials following strictly standardized definitions and nomenclature.
耐用于治疗结核病（TB）的药物的耐药性的出现，尤其是耐多药结核病（MDR-TB），定义为至少对利福平（rifampicin）和异烟肼（isoniazid）耐药，已成为许多国家重大的公共卫生难题，也是有效控制全球结核病的障碍。了解与 HIV 相关的 MDR-TB 对于提供治疗 HIV 和耐药性结核病的策略至关重要。更好地了解药物作用和耐药性的基础是开发诊断策略、新型药物和治疗方案的关键，也是研究耐药菌株致病性的一种方法。应根据严格标准化的定义和命名法，在操作领域临床试验中测试 DOTS-Plus 等策略在管理 MDR-TB 患者方面的有效性。
